CEO Sam Cobb has recently been profiled by US business journal Life Science Leader, taking readers through her 12 year journey as the founding CEO of a biotech company. It has been “a roller-coaster ride of personal growth” including navigating capital raising, rebounding from deals that fell apart and managing setbacks in moving the lead candidate through to clinical trials.
You can view the article on the Life Science Leader website here.
If you would like to learn more about AdAlta’s lead candidate, AD-214, for Idiopathic Pulmonary Fibrosis click here.
AdAlta’s Managing Director and Chief Executive Officer Sam Cobb recently provided an update to the Morgans network on the company’s progress. Check out the video below and click here to view AdAlta’s latest ASX announcements.
Sam shared her views on women putting themselves for leadership roles, the imbalance between more women in science but a lack of growth at the top of the corporate ladder as well as her experience dealing with investors, where there is lack of women on the other side of the table also.
“I think we now, within the Pharmaceuticals industry and in biotechnology, understand that there is three main things we have to keep in mind: the right target, the right drug and the right patient”
These words from AdAlta Scientific Advisory Board member Dr John Westwick summed up AdAlta’s third annual Special Investor/Analyst Briefing held on January 31, 2019. Check out the short highlights video to see why these pharmaceutical veterans believe that AdAlta’s lead program, AD-214, has the exciting potential to meet all of these three key criteria.
With AD-214 moving through final preclinical stages before entering clinical trials in 2020, the day focused on the pathway to drug development and brought together a range of medical, scientific and pharmaceutical experts.
Investors and analysts also heard about AdAlta’s progress as well as the need for new IPF treatments and the benefits of investing in Australian biotechnology companies. It included a panel session on ‘What a good drug looks like‘, an often under-appreciated topic when developing a new therapeutic.
A highlight of the day was hearing from Idiopathic Pulmonary Fibrosis patient Bill Van Nierop. Bill discussed the impact of IPF and his tremendous efforts to raise awareness of the disease – one that kills more people in Australia than breast cancer but “gets no mention, anywhere”.
Individual Speaker Presentations
‘An IPF patient’s perspective’
IPF Clinician Dr Glen Westall ‘Current state of play in IPF’
Clinician Dr Steve Felstead – ‘The IPF Landscape’
AdAlta Chief Operating Officer – Dr Dallas Hartman ‘Manufacturing of AD-214’
AdAlta non-executive Director – Dr Robert Peach ‘Therapeutic Fc Fusion Proteins’
Panel Discussion – Dr Brian Richardson, Dr John Westwick, Dr Steve Felstead and Dr Robert Peach ‘What does a good drug look like?’
Chairman and Founder of Private Portfolio Managers – Hugh MacNally ‘Investing in Biotech, what does it take?’
AdAlta CEO – Sam Cobb – ‘Update on lead program AD-214’
AdAlta CEO Sam Cobb recently spoke to Danielle Doporto from Proactive Investors Australia in their Sydney studio. Sam gave an overview of AdAlta’s i-body platform technology and and it’s unique ability to reach difficult to access targets. Sam also demonstrated the market potential of AdAlta’s lead program, AD-214, for the treatment of the lung condition, Idiopathic Pulmonary Fibrosis, where currently available therapeutics generate yearly sales of US$1.5-2b.
AdAlta is one of the presenting companies at the Proactive Investors CEO Sessions to be held in Sydney on February 18 and Melbourne on February 19.
If you would like to receive further updates from AdAlta, including upcoming investor events, subscribe here.
AdAlta CEO Sam Cobb will be presenting at upcoming February investor events held in Sydney, Melbourne and Brisbane. An introduction to AdAlta’s technology, an update on progress of the lead program as well as the milestones to come in 2019 will be provided. Click on the links below to find out more information for each event and to register to attend. The latest company presentation can also be accessed here.
AdAlta has released an updated brochure on Idiopathic Pulmonary Fibrosis (IPF), the debilitating lung disease for which the i-body therapeutic, AD-214, is currently in preclinical development.
The brochure displayed below introduces ‘What is IPF?’, the market potential, current therapeutics in development as well as AdAlta unique approach to tackling this disease through an i-body to a drug target called CXCR4.
The brochure can be downloaded here, more information on AdAlta’s lead i-body program, AD-214, can be found here and if you would like to receive updates on AdAlta’s progress subscribe here.
AdAlta CEO Sam Cobb spoke with Proactive Investors during her recent trip to San Francisco to attend Biotech Showcase, meeting with investors and pharmaceutical companies.
Take a look at the brief interview below which provides an update on the progress of AdAlta’s lead program, AD-214, a novel i-body therapy for the treatment of the lung condition, Idiopathic Pulmonary Fibrosis.
If you would like to stay informed of AdAlta’s progress, subscribe to receive updates here.
AdAlta CEO Sam Cobb provided an an update to the Morgans network in December 2018 on the progress of AdAlta’s lead candidate, AD-214. This included an update on the manufacturing of AD-214 being completed by Selexis and KBI Biopharma as well as AdAlta’s progress towards clinical trials slated to commence early 2020. The interview can be viewed below and AdAlta’s latest company presentation can be found here.
2018 has been a very productive year for AdAlta and the company is pleased provide its second shareholder update for the year. The shareholder update, which can be viewed online below and downloaded here, includes an interview with COO Dallas Hartman on the manufacturing progress for AD-214 and a summary of AdAlta’s participation in the Australian Technologies Competition.
